Novo Nordisk's Chief Executive Officer, Mike Doustdar, is apparently attempting to thwart Pfizer's acquisition of the biotech company Metsera. (Archive photo). Photo: Ludovic Marin/Ritzau Scanpix
Novo wants to overtake competitor with a buyout offer
Novo Nordisk has not given up its attempt to acquire the biotech company Metsera, which was previously set to be acquired by the pharmaceutical company Pfizer. Novo Nordisk has submitted a bid for $56.5 per share, plus up to $21.25 per share contingent on certain milestones. The offer has been...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?